This inaugural edition of DeciBio’s IVD report provides an overview of the In Vitro Diagnostics (IVD) market from 2012 to 2018. IVD companies offer diagnostic instruments, reagents and services to clinical laboratories. These tests are marketed and sold specifically for the purpose of patient diagnosis and treatment decision making, and as such must be approved for this purpose by governing regulatory bodies (e.g. FDA or CE Mark approval). This market report excludes laboratory developed tests (LDTs) since they do not use IVD kits / assays. The ~$60B worldwide IVD market is expected to grow at ~5% through 2018. This market is currently moderately consolidated, with top 15 manufacturers (including Roche, Abbott, Danaher, Siemens, Becton Dickenson, Thermo Fisher, Alere, OCD, Sysmex, BioMerieux, LifeScan (J&J), Bio-Rad, Werfen, Hologic and Phillips) representing over 75% of sales. However, many mid-size (e.g., Cepheid, Luminex) and smaller emerging (e.g., Illumina, NanoString) players are highlighted and included in this report as well. The analysis conducted for this report includes careful triangulation of market growth with past and forecasted organic growth from key players. Our market model provides robust segmentation and growth segmented by: • Technology: clinical chemistry, culture, flow cytometry, glucose strip monitoring, immunoassay, mass spectrometry, molecular diagnostics and tissue diagnostics • Therapeutic area: autoimmune, blood screening, cardiovascular, diabetes, endocrine, general chemistry, hemostasis, hematology, infectious disease, metabolic disease, microbiology, oncology, reproductive, transplant, and other • Geography: North America, Europe, LATAM, Asia-Pac, China, Japan and ROW • Competitor: Roche, Abbott, Danaher, Siemens, Becton Dickinson, Thermo Fisher, Alere, OCD, Sysmex, BioMérieux, LifeScan (J&J), Bio-Rad, Werfen, Hologic, Phillips and many others In addition to the quantitative market model, we detail market trends (e.g., clinical adoption of next generation sequencing (NGS), changing trends in lab throughput needs), drivers (e.g., infectious disease testing switching from low priced culture to higher priced MDx) and moderators (e.g., pricing and reimbursement pressures), and a high level technology and revenue breakdown for key competitors. All data are based on manufacturer sales as publically reported, other public data and over 1,000 customer interviews with customers and industry participants conducted over the last year.